微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 23.1% | 94.27% | 43.45% | 127/159 | 31.52% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 16.1% | -28.44% | -10.82% | 144/159 | 51.8% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 18.06% | -42.06% | 13.93% | 143/159 | 22.98% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 15.85% | -58.41% | 33.29% | 144/159 | 33.39% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 11.89% | -70.03% | -47.16% | 143/159 | 51.73% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 22.5% | -49.34% | -27.79% | 137/159 | 51.53% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 31.16% | -37.05% | -18.23% | 119/159 | 32.76% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 38.11% | -26.79% | -3.93% | 110/159 | 38.65% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 39.67% | -21.8% | -10.69% | 100/159 | 52.91% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 44.42% | -23.65% | -10.27% | 93/159 | 53.74% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 49.5% | -18.38% | -4.91% | 82/159 | 6.69% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 52.06% | -14.73% | 2.61% | 79/159 | 21.74% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 50.73% | -17.09% | -12.8% | 78/159 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 58.18% | -15.27% | -4.07% | 68/159 | 55.21% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 60.65% | -14.95% | -0.66% | 55/159 | 47.01% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 61.05% | -13.46% | -0.22% | 58/159 | 47.45% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 61.19% | -20.59% | -10.89% | 50/159 | 54.21% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 68.67% | -6.06% | -3.71% | 43/159 | -144.37% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 71.31% | -3.79% | 1.08% | 32/159 | 56.57% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 70.55% | -0.71% | -8.44% | 32/159 | 54.32% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 77.06% | 8.04% | 5.42% | 23/159 | 55.5% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 73.09% | 2.34% | -1.38% | 34/159 | -1213.38% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 74.12% | 4.82% | 4.31% | 20/159 | 55.47% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 71.06% | 1.94% | -0.37% | 29/159 | 55.47% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 71.32% | -0.28% | -0.15% | 22/159 | 51.37% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 71.42% | 9.06% | 1.01% | 34/159 | -205.91% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 70.71% | 1.95% | 1.43% | 22/159 | 54.25% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 69.71% | -2.63% | -2.53% | 20/159 | 53.68% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 71.52% | 9.82% | 9.2% | 19/159 | 54.19% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 65.49% | 1.24% | -5.57% | 32/159 | 52.58% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 69.35% | 5.61% | -3.13% | 19/159 | 49.32% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 71.59% | 11.56% | 9.94% | 16/159 | 48.02% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 65.12% | 1.26% | 0.66% | 19/159 | 46.89% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 64.69% | -3.16% | -1.49% | 26/159 | 48.44% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 65.67% | 2.46% | 2.34% | 17/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 64.17% | 3.51% | -0.22% | 22/159 | 46.2% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 64.31% | 0.98% | -3.72% | 15/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 66.8% | 13.83% | 4.22% | 19/159 | 46.24% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 64.09% | 7.18% | 3.38% | 15/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 62% | 5.07% | -2.66% | 20/159 | 45.36% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 63.69% | 25.16% | 8.53% | 14/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |